Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133–60.Web of ScienceGoogle Scholar
Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998;83:403–9.Google Scholar
New MI, Gertner JM, Speiser PW, Del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J Endocrinol Invest 1989;12:91–5.Google Scholar
Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:3070–8.Google Scholar
Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23:193–208.Google Scholar
Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press, 1959.Google Scholar
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–41.Google Scholar
Li H, Ji CY, Zong XN, Zhang YQ. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi 2009;47:487–92.Google Scholar
Li H, Ji CY, Zong XN, Zhang YQ. Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi 2009;47:493–8.Google Scholar
Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2–9 years allowing for heights of parents. Arch Dis Child 1970;45:755–62.Google Scholar
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the growth hormone research society, the lawson wilkins pediatric endocrine society, and the european society for paediatric endocrinology workshop. J Clin Endocrinol Metab 2008;93:4210–7.Web of ScienceGoogle Scholar
Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001;138:26–32.Google Scholar
Hargitai G, Solyom J, Battelino T, Lebl J, Pribilincova Z, et al. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res 2001;55:161–71.Google Scholar
Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, et al. Long-term persistence in use of statin therapy in elderly patients. J Am Med Assoc 2002;288:455–61.Google Scholar
Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. [Consensus statement for the diagnosis and treatment of central precocious puberty (2015)]. Zhonghua Er Ke Za Zhi 2015;53:412–8.Google Scholar
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752–62.Web of ScienceGoogle Scholar
Muthusamy K, Elamin MB, Smushkin G, Murad MH, Lampropulos JF, et al. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010;95:4161–72.Web of ScienceGoogle Scholar
Brunelli VL, Russo G, Bertelloni S, Gargantini L, Balducci R, et al. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. J Pediatr Endocrinol Metab 2003;16:277–83.Google Scholar
Manoli I, Kanaka-Gantenbein C, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol (Oxf) 2002;57:669–76.Google Scholar
Jaaskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res 1997;41:30–3.Google Scholar
Schwartz RP. Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia. J Pediatr 2001;138:3–5.Google Scholar
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007;92:1635–9.Google Scholar
Hermanussen M, Cole J. The calculation of target height reconsidered. Horm Res 2003;59:180–3.Google Scholar
Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). J Pediatr Endocrinol Metab 2012;25:977–81.Web of ScienceGoogle Scholar
Sarafoglou K, Addo OY, Turcotte L, Otten N, Wickremasinghe A, et al. Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort. J Pediatr 2014;164:1141–6.e1.Google Scholar
Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, et al. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab 2009;94:3882–8.Web of ScienceGoogle Scholar
Aycan Z, Ocal G, Berberoglu M, Cetinkaya E, Adiyaman P, et al. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential. J Pediatr Endocrinol Metab 2006;19:245–51.Google Scholar
Damiani D, Damiani D. Pharmacological management of children with short stature: the role of aromatase inhibitors. J Pediatr (Rio J) 2007;83:S172–7.Google Scholar
Soliman AT, AlLamki M, AlSalmi I, Asfour M. Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Metabolism 1997;46:513–7.Google Scholar
Guven A, Nurcan Cebeci A, Hancili S. Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty. Hormones (Athens) 2015;14:265–71.Google Scholar
Cornean RE, Hindmarsh PC, Brook CG. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998;78: 261–3.Google Scholar
About the article
Published Online: 2016-04-07
Published in Print: 2016-07-01
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.